Immunized women were protected against HPV 16/18 and associated cervical abnormalities.
Human papillomavirus (HPV) immunization campaigns are typically directed at adolescent girls who are not yet sexually active; however, adult women are potentially susceptible to new infection. In an industry-sponsored international study, investigators randomized 5752 women older than 25 to receive HPV 16/18 vaccine or placebo. For this interim analysis, participants were followed for persistent HPV infection and cervical intraepithelial grade ≥1 for a mean of 44 months (the study is planned to continue for 7 years).
In the cohort of women who were DNA-negative and seronegative at baseline for HPV 16/18, overall efficacy was 81% (97.7% confidence interval, 52–94) and was similar in women aged 26 to 35 and aged 36 to 45. The vaccine also prot…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)